APA (7th ed.) Citation

Qin, Y., Zhu, H., Liu, Y., Wang, Y., Shi, H., Lai, Y., . . . Huang, X. (2013). PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. Leukemia & Lymphoma, 54(7), 1442. https://doi.org/10.3109/10428194.2012.743656

Chicago Style (17th ed.) Citation

Qin, Ya-Zhen, et al. "PRAME and WT1 Transcripts Constitute a Good Molecular Marker Combination for Monitoring Minimal Residual Disease in Myelodysplastic Syndromes." Leukemia & Lymphoma 54, no. 7 (2013): 1442. https://doi.org/10.3109/10428194.2012.743656.

MLA (9th ed.) Citation

Qin, Ya-Zhen, et al. "PRAME and WT1 Transcripts Constitute a Good Molecular Marker Combination for Monitoring Minimal Residual Disease in Myelodysplastic Syndromes." Leukemia & Lymphoma, vol. 54, no. 7, 2013, p. 1442, https://doi.org/10.3109/10428194.2012.743656.